NOG antibody (AA 156-170)
-
- Target See all NOG Antibodies
- NOG (Noggin (NOG))
-
Binding Specificity
- AA 156-170
-
Reactivity
- Human, Mouse, Rat
-
Host
- Rabbit
-
Clonality
- Polyclonal
-
Conjugate
- This NOG antibody is un-conjugated
-
Application
- Western Blotting (WB)
- Specificity
- Reacts with Noggin from human, mouse and rat
- Purification
- Antigen affinity purified
- Immunogen
- Synthetic peptide comprising residues 156-170 [PVLYAWNDLGSRFWP] of the human Noggin protein
- Isotype
- IgG
- Top Product
- Discover our top product NOG Primary Antibody
-
-
- Application Notes
-
Working dilution: Optimal dilution should be determined by the end user.
The following are guidelines only:
- WB : 1/1 000 to 1/2 000 - Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
- PBS, Sodium azide 0.02 %
- Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C/-20 °C
- Storage Comment
- Short term storage at +4°C. For extended periods store in aliquots at -20°C. Antibodies are guaranteed for 6 month from date of receipt.
- Expiry Date
- 6 months
-
- Target
- NOG (Noggin (NOG))
- Alternative Name
- Noggin (NOG Products)
- Synonyms
- SYM1 antibody, SYNS1 antibody, nog-A antibody, nog1 antibody, noggin-1 antibody, noggin antibody, noggin antibody, noggin L homeolog antibody, noggin protein antibody, NOG antibody, Nog antibody, nog.L antibody, noggin antibody
- Background
- Noggin is involved in numerous developmental processes, such as neural tube fusion and joint formation. The morphogenesis of organs is initiated by a downgrowth from a layer of epithelial stem cells. This process is achieved through the receipt of signals from 1) a WNT protein (WNT3A) to stabilize beta-catenin, and 2) Noggin, which is a bone morphogenetic protein inhibitor.Noggin mutations in unrelated families with proximal symphalangism (SYM1) and multiple synostoses syndrome (SYNS1) have been identified, which have multiple joint fusion as their principal defect.
- Pathways
- Stem Cell Maintenance, Tube Formation
-